Ibrexafungerp (brand name Brexafemme) is a first-in-class oral antifungal approved for treating vaginal yeast infections, and it works through a mechanism that sets it apart from both the older azole drugs and the injectable echinocandins that hospitals rely on for serious fungal infections. It belongs to a new drug class called triterpenoid antifungals, sometimes referred to as “fungerps,” and it targets the same structure in the fungal cell wall that echinocandins do but binds at a different site.1PubMed Central. Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor That distinction matters more than it sounds like it should, especially for people dealing with infections that do not respond to standard treatment.
How Ibrexafungerp Works
Fungal cells depend on a structural component in their cell walls called beta-glucan. Ibrexafungerp blocks the enzyme responsible for building that component, weakening the wall and ultimately causing the cell to burst. This is the same general approach used by echinocandins like caspofungin and micafungin, which have been workhorses in hospital antifungal care for years. The critical difference is that ibrexafungerp latches onto a different spot on the target enzyme.2PubMed Central. Antifungal resistance, combinations and pipeline: oh my! Because of this different binding site, fungi that have developed resistance to echinocandins do not automatically resist ibrexafungerp. And unlike echinocandins, which must be given through an IV, ibrexafungerp is taken by mouth, which opens up outpatient uses that IV-only drugs cannot easily serve.
Approved Uses
The primary approved use of ibrexafungerp is treating vulvovaginal candidiasis, commonly known as a vaginal yeast infection. This is an extremely common condition, and for most people fluconazole (Diflucan) handles it well. Ibrexafungerp exists for the substantial number of cases where fluconazole is not appropriate: the person cannot take azole antifungals, the infection is caused by a species that resists azoles, or the person simply prefers a non-azole option.
In randomized trials against placebo, ibrexafungerp showed significantly higher rates of clinical cure and complete symptom resolution. A meta-analysis pooling placebo-controlled trial data found that women receiving ibrexafungerp were roughly twice as likely to achieve clinical cure as those on placebo.3PubMed. Ibrexafungerp for the treatment of vulvovaginal candidiasis: A systematic review and meta-analysis of randomized placebo-controlled trials A separate meta-analysis of randomized controlled trials comparing ibrexafungerp to both fluconazole and placebo found it had superior clinical cure and mycological eradication rates overall.4PubMed Central. Efficacy and safety of ibrexafungerp in the treatment of vulvovaginal candidiasis: A meta-analysis of randomized controlled trials
Ibrexafungerp also has approval for reducing recurrences in women with recurrent vulvovaginal candidiasis, defined as having multiple episodes within a year. A phase 3 trial found that monthly dosing reduced the rate of mycologically proven recurrence: about 71% of women on ibrexafungerp had no recurrence over the treatment period compared with roughly 59% on placebo. That benefit held for four months after the last dose, with recurrence-free rates of about 65% versus 54%.5American Journal of Obstetrics and Gynecology. Efficacy and safety of monthly oral ibrexafungerp for the reduction of recurrent vulvovaginal candidiasis: a phase 3, randomized, double-blind, placebo-controlled trial For anyone who has dealt with the cycle of repeated yeast infections, the idea of a once-monthly pill that meaningfully cuts recurrence rates is a real step forward.
Dosage and Administration
One of the appealing features of ibrexafungerp for acute yeast infections is its dosing simplicity. The standard regimen for an acute episode is a one-day course: two tablets taken about 12 hours apart. That is it. You do not need to wait for a meal, and the drug reaches high concentrations in vaginal tissue.6PubMed. Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis For the prevention of recurrent infections, the regimen shifts to once-monthly dosing over several months.
The drug is absorbed well when taken by mouth. Preclinical pharmacokinetic studies showed good oral bioavailability across species, and the drug’s elimination half-life in animals suggested once-daily dosing would translate well to humans.7PubMed Central. Pharmacokinetics and Pharmacodynamics of Ibrexafungerp In practice, the one-day acute dosing schedule means you are not tracking a multi-day pill course, which reduces the chances of skipping doses or stopping early.
Side Effects
The side effect profile of ibrexafungerp is dominated by gut-related symptoms. The most commonly reported adverse reactions in clinical trials were diarrhea, nausea, abdominal pain, dizziness, and vomiting.8American Journal of Health-System Pharmacy. Ibrexafungerp: A new triterpenoid antifungal These are generally mild to moderate and self-limiting.
A meta-analysis drilling into the safety data across trials found the gastrointestinal side effects were more common with ibrexafungerp than with fluconazole or placebo. The risk of nausea was roughly two and a half times higher, and the risk of diarrhea was about four times higher compared to the control groups. Abdominal pain showed a trend toward being more common but did not reach statistical significance.9Heliyon. Efficacy and safety of ibrexafungerp in the treatment of vulvovaginal candidiasis: A meta-analysis of randomized controlled trials A phase 1 safety trial in healthy volunteers confirmed this pattern: all adverse events were mild or moderate, none were serious, and all resolved on their own. No one dropped out of the study because of side effects.10PubMed Central. Safety, tolerability, and pharmacokinetics of ibrexafungerp in healthy Chinese subjects: a randomized, double-blind, placebo-controlled phase 1 trial
In practical terms, if you take ibrexafungerp for an acute yeast infection, you might have a day or two of loose stools or mild nausea. For most people this resolves quickly and does not require treatment. The one-day dosing helps here because you are not prolonging exposure the way a multi-day antifungal course would.
Pregnancy and Reproductive Considerations
Ibrexafungerp is not recommended during pregnancy. Animal studies have shown evidence of harm to developing fetuses, and there is not enough human data to establish safety. A narrative review of antifungal safety in pregnancy grouped ibrexafungerp alongside other newer antifungals (oteseconazole and rezafungin) as agents that should be avoided because of limited human data and animal teratogenicity findings.11Journal of Applied Pharmaceutical Science. Systemic Antifungal Safety During Pregnancy: A Narrative Review If you are pregnant or planning to become pregnant, this is a drug to discuss alternatives for. Effective contraception during treatment is standard guidance.
How It Compares to Fluconazole
Fluconazole remains the default first-line oral treatment for vaginal yeast infections in most guidelines, and for good reason: it is cheap, effective, well-tolerated, and comes as a single pill. So where does ibrexafungerp fit?
A phase 2 head-to-head trial found similar clinical cure rates at the initial follow-up visit: about 52% for ibrexafungerp and 58% for fluconazole. But by day 25, the picture shifted. Among patients who achieved early clinical cure, 70% of those in the ibrexafungerp group remained symptom-free compared with 50% on fluconazole. Patients on ibrexafungerp were also far less likely to need rescue antifungal medication during the study period: about 4% versus 29%.12PubMed Central. Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis That lower need for rescue medication is a meaningful real-world advantage, even if the initial cure rates looked similar.
A caveat: the phase 2 study was small and was not designed or powered to definitively prove ibrexafungerp is better than fluconazole. The phase 3 trials that led to approval compared ibrexafungerp to placebo, not fluconazole, so the direct head-to-head evidence remains limited. A cost-effectiveness analysis conducted for the UK health system found ibrexafungerp to be slightly more effective than fluconazole but substantially more expensive, concluding it had an unfavorable net benefit in that setting.13PubMed. A cost-effectiveness analysis of the use of oral ibrexafungerp versus fluconazole for acute vulvovaginal candidiasis in the UK NHS primary care service In other words, for a straightforward yeast infection that fluconazole can handle, fluconazole is still the sensible choice for most people. Ibrexafungerp earns its place when fluconazole fails, is contraindicated, or when the infecting organism is resistant to azoles.
Activity Against Drug-Resistant Candida
This is arguably where ibrexafungerp’s long-term importance lies. Candida auris is a species that has alarmed infectious disease specialists worldwide because it can resist multiple classes of antifungal drugs simultaneously. Ibrexafungerp has shown consistent laboratory activity against C. auris, including strains that resist both fluconazole and echinocandins.14PubMed Central. In Vitro Activity of Ibrexafungerp (SCY-078) against Candida auris Isolates as Determined by EUCAST Methodology and Comparison with Activity against C. albicans and C. glabrata and with the Activities of Six Comparator Agents In animal models, it was effective against C. auris even when treatment was delayed after infection.15PubMed Central. Ibrexafungerp Demonstrates In Vitro Activity against Fluconazole-Resistant Candida auris and In Vivo Efficacy with Delayed Initiation of Therapy in an Experimental Model of Invasive Candidiasis
Broader testing against bloodstream Candida isolates has confirmed activity against both echinocandin-resistant and azole-resistant strains.16PubMed. In vitro activity of ibrexafungerp against Candida species isolated from blood cultures. Determination of wild-type populations using the EUCAST method The limited cross-resistance with echinocandins, despite sharing the same general target, is a direct consequence of that different binding site on the glucan synthase enzyme. This means ibrexafungerp could serve as a backup for patients with invasive candidiasis who have run out of other options, though its approved indication currently remains limited to vaginal candidiasis.
The Low-pH Advantage
The vagina has a naturally acidic environment, typically around pH 4 to 4.5. Most antifungals do not perform better at low pH, and some actually become less effective. Fluconazole, for example, tends to show higher minimum inhibitory concentrations (meaning it works less well) at lower pH values. Ibrexafungerp does the opposite: its potency increases dramatically in acidic conditions. Testing showed that its activity was much stronger at pH 4.5 compared to neutral pH.17PubMed Central. A Novel 1,3-Beta-d-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis Combined with the drug’s ability to concentrate in vaginal tissue at levels exceeding plasma, this makes for a pharmacologic profile that is well-matched to the specific environment of vaginal candidiasis.18PubMed Central. Ibrexafungerp: Mechanism of Action, Clinical, and Translational Science
This pH-dependent boost is not just a laboratory curiosity. It is part of why the drug was developed for vaginal infections specifically before broader indications. The vaginal niche is a place where the drug’s pharmacology plays to its strengths in a way that fluconazole’s does not.
Beyond Vaginal Yeast Infections
While vaginal candidiasis is the current approved indication, clinical research has explored ibrexafungerp for harder-to-treat fungal infections. An ongoing open-label phase 3 study (called FURI) enrolled patients with invasive or severe mucocutaneous Candida infections who had either failed standard antifungal therapy or could not tolerate it. An interim analysis of 41 patients found that over half achieved a complete or partial response, with the drug showing activity even against non-albicans Candida species that tend to be harder to treat.19Open Forum Infectious Diseases. 1248. Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI)
There is also interest in the drug’s activity against Candida biofilms, the organized communities of fungal cells that coat medical devices like catheters and are notoriously difficult to treat. A laboratory study comparing several antifungals found that while all drugs needed much higher concentrations to kill biofilm-associated cells than free-floating ones, ibrexafungerp outperformed some alternatives against certain C. auris biofilm strains.20PubMed Central. Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strains Biofilm infections are a particular challenge in hospitalized patients with central lines or other indwelling devices, and new tools against them are badly needed.
Drug Interactions and Practical Considerations
One of the practical advantages clinicians have noted about ibrexafungerp is its low risk for clinically meaningful drug interactions.6PubMed. Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis Fluconazole, by contrast, is a potent inhibitor of certain liver enzymes and can significantly alter the levels of drugs processed through those pathways, including blood thinners, certain diabetes medications, and some psychiatric drugs. For someone on a complex medication regimen, ibrexafungerp’s cleaner interaction profile is a legitimate advantage, though you should still inform your prescriber of everything you take.
The drug is also notable for what it does not require: no IV access, no monitoring bloodwork during a short course, and no food restrictions with dosing. For an acute episode, the entire treatment is two doses in a single day. Compare this to topical antifungal creams, which can require several days of messy application, or to fluconazole, which for some people requires a follow-up dose days later if the first one does not resolve things completely.
Use in Adolescents and Children
Current labeling extends ibrexafungerp dosing to patients aged 12 and older, but the evidence base for younger patients is thin. No patients under 18 were enrolled in the phase 3 trials for acute vaginal candidiasis. The approval for the 12-and-older group was extrapolated from adult data combined with safety information from post-menarchal adolescents.21Journal of the Pediatric Infectious Diseases Society. Pipeline of Novel Antifungals for Invasive Fungal Disease in Transplant Recipients: A Pediatric Perspective For younger children or for invasive fungal infections in the pediatric population, dedicated studies are still needed. Pediatric infectious disease specialists are watching ibrexafungerp with interest, particularly for transplant recipients who are vulnerable to invasive Candida infections and have limited oral antifungal options.
Where Ibrexafungerp Fits in the Bigger Antifungal Landscape
The antifungal toolkit has been remarkably small compared to what is available for bacterial infections. For decades, clinicians had essentially three classes to work with: azoles (fluconazole, voriconazole), polyenes (amphotericin B), and echinocandins (caspofungin, micafungin, anidulafungin). Resistance has been steadily eroding the reliability of each. Ibrexafungerp represents a genuinely new mechanism in a field that has not seen one in over 20 years.
Its current approved niche is narrow: vaginal yeast infections. But the features that make it interesting extend well beyond that. An oral drug with activity against azole-resistant and echinocandin-resistant Candida, enhanced potency in acidic environments, good tissue penetration, and limited drug interactions is a tool with clear potential for broader use. The ongoing FURI trial and other studies exploring invasive candidiasis are the next chapters in what could be a much larger story for this drug class. Whether the evidence eventually supports wider indications will depend on the outcomes of those trials, and the science here is genuinely still being written.